文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤

纳波拉非尼联合或不联合斯巴达利珠单抗在携带MAPK信号通路改变的晚期实体瘤成人患者中的首次人体研究

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
PubMed 文献 · Eur J Cancer · 2023-11-21

该首次人体1期研究纳入142例携带MAPK通路改变的晚期实体瘤患者,评估纳波拉非尼单药或联合斯巴达利珠单抗的剂量递增与扩展,确定单药最大耐受剂量/推荐扩展剂量为600 mg每日两次,联合方案推荐扩展剂量为400 mg每日两次,安全性可接受,药效学有活性,抗肿瘤活性有限。

要点

  • 纳波拉非尼单药最大耐受剂量/推荐扩展剂量为600 mg每日两次,联合斯巴达利珠单抗推荐扩展剂量为400 mg每日两次。
  • 单药组5例患者发生7例次剂量限制性毒性,联合组未发生剂量限制性毒性。
  • 联合扩展组NRAS突变黑色素瘤和KRAS突变非小细胞肺癌分别出现1例完全缓解和3例部分缓解。

核心结论

  • 纳波拉非尼联合或不联合斯巴达利珠单抗安全性可接受,具有药效学活性,抗肿瘤活性有限。
  • 其他纳波拉非尼联合治疗目前正在研究中。

研究设计与样本

  • 首次人体1期研究,设两个剂量递增组:纳波拉非尼单药组(起始100 mg每日一次)和纳波拉非尼(起始为推荐剂量/方案)联合斯巴达利珠单抗(400 mg每4周一次)组。
  • 纳波拉非尼联合斯巴达利珠单抗剂量扩展部分入组KRAS突变非小细胞肺癌和NRAS突变黑色素瘤患者。
  • 共纳入142例患者,其中纳波拉非尼剂量递增组87例,纳波拉非尼联合斯巴达利珠单抗剂量递增组12例,纳波拉非尼联合斯巴达利珠单抗剂量扩展组43例。
  • 主要目标为确定最大耐受剂量/推荐扩展剂量,并评估耐受性和安全性。

主要发现

  • 纳波拉非尼的最大耐受剂量/推荐扩展剂量为600 mg每日两次;联合斯巴达利珠单抗的推荐扩展剂量为400 mg每日两次。
  • 纳波拉非尼递增组5例患者发生7例次剂量限制性毒性:血小板计数降低(1200 mg每日一次);神经痛、斑丘疹、瘙痒(600 mg每日两次);血胆红素升高、低钠血症、外周感觉神经病(800 mg每日两次)。
  • 纳波拉非尼联合斯巴达利珠单抗组未发生剂量限制性毒性。
  • 最常见治疗相关不良事件:纳波拉非尼组为皮疹和痤疮样皮炎(各24.1%);联合递增组为恶心和瘙痒(各33.3%);联合扩展组为皮疹(39.5%)。
  • 纳波拉非尼降低肿瘤中DUSP6表达;纳波拉非尼递增组出现2例部分缓解,联合组NRAS突变黑色素瘤和KRAS突变非小细胞肺癌分别出现1例完全缓解和3例部分缓解。

关键数值与推荐

  • 纳波拉非尼单药最大耐受剂量/推荐扩展剂量为600 mg每日两次。
  • 纳波拉非尼联合斯巴达利珠单抗推荐扩展剂量为400 mg每日两次。
  • 纳波拉非尼单药剂量限制性毒性:血小板计数降低(1200 mg每日一次)、神经痛/斑丘疹/瘙痒(600 mg每日两次)、血胆红素升高/低钠血症/外周感觉神经病(800 mg每日两次)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations. METHODS: This first-in-human phase 1 study had two dose-escalation arms: single-agent naporafenib (starting at 100 mg once-daily [QD]) and naporafenib (starting at the recommended dose/regimen)/spartalizumab (400 mg every 4 weeks). The naporafenib/spartalizumab dose-expansion part enrolled patients with KRAS-mutated non-small cell lung cancer (NSCLC) and NRAS-mutated melanoma. The primary objectives were to establish the maximum tolerated doses (MTD)/recommended doses for expansion (RDE) and evaluate tolerability and safety. RESULTS: A total of 142 patients were included in the naporafenib dose-escalation (n = 87), naporafenib/spartalizumab dose-escalation (n = 12) and naporafenib/spartalizumab dose-expansion (n = 43) arms. The MTD/RDE of naporafenib was 600 mg twice-daily (BID). In naporafenib escalation, five patients experienced 7 dose-limiting toxicities: decreased platelet count (1200 mg QD); neuralgia, maculopapular rash, pruritus (600 mg BID); increased blood bilirubin, hyponatremia, peripheral sensory neuropathy (800 mg BID). No DLTs occurred in the naporafenib/spartalizumab arm: the RDE was established at 400 mg BID. The most common treatment-related adverse events were rash and dermatitis acneiform (each 24.1%; naporafenib), nausea and pruritus (each 33.3%; naporafenib/spartalizumab; escalation) and rash (39.5%; naporafenib/spartalizumab; expansion). Naporafenib reduced DUSP6 expression in tumors. Two partial responses (PRs) occurred in naporafenib escalation, and 1 complete response and 3 PRs in the naporafenib/spartalizumab NRAS-mutated melanoma and KRAS-mutated NSCLC arms, respectively. CONCLUSIONS: Naporafenib, with or without spartalizumab, showed an acceptable safety profile, pharmacodynamic activity and limited antitumor activity. Additional naporafenib combination therapies are currently under investigation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Janku F, Kim TM, Iyer G, et al. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2023. PMID: 38039779. doi:10.1016/j.ejca.2023.113458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。